# Ivermectin Nasal Spray for COVID19 Patients

> **NCT04510233** · PHASE2 · UNKNOWN · sponsor: **Tanta University** · enrollment: 60 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Ivermectin nasal
- **DRUG:** Ivermectin oral
- **OTHER:** standard care

## Key facts

- **NCT ID:** NCT04510233
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2020-10
- **Final completion:** 2020-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510233, "Ivermectin Nasal Spray for COVID19 Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04510233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*